Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer

被引：7

作者：

Rescigno, Pasquale ^{[1
,2
]}

Chandler, Robert ^{[1
]}

de Bono, Johann ^{[1
]}

机构：

[1] Inst Canc Res, 15 Cotswold Rd, London SM2 5NG, England

[2] AOU Federico II, Dept Translat Med Sci, Dept Clin Med & Surg, Naples, Italy

来源：

CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE | 2018年 / 12卷 / 03期

关键词：

poly (ADP-ribose) polymerase inhibitors; prostate cancer; reversion mutation; CELL-FREE DNA; POLY(ADP-RIBOSE) POLYMERASE; BONE METASTASES; REPAIR; RESISTANCE; PATHWAY; BRCA2; MUTATIONS; CARCINOMA; OLAPARIB;

D O I：

10.1097/SPC.0000000000000358

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Purpose of review Poly (ADP-ribose) polymerase inhibitors (PARPi) are approved drugs for the treatment of ovarian and breast cancer and currently under investigation for the treatment of prostate cancer and other malignancies with aberrations in homologous recombination DNA repair. This review summarizes literature published during 2017 concerning the relevance of PARPi in prostate cancer and presents new evidence on mechanisms of resistance and biomarkers of response. Recent findings The approval of several PARPi (olaparib, rucaparib, and niraparib) has driven the focus of anticancer treatment on synthetic lethality in prostate cancer too. Despite anecdotal reports of long-term responders, most cancers become resistant to these therapies. Different mechanisms of primary and acquired resistance to PARPi have been recently investigated including loss of PARP1 expression, BRCA mutations with partial function, and acquisition of reversion restoration of function mutations. Summary Here, we discuss the importance of PARPi in metastatic castration-resistant prostate cancer and discuss the possible mechanisms of resistance.

引用

页码：339 / 343

页数：5

共 51 条

[1] The Molecular Taxonomy of Primary Prostate Cancer [J].

Abeshouse, Adam ;

Ahn, Jaeil ;

Akbani, Rehan ;

Ally, Adrian ;

Amin, Samirkumar ;

Andry, Christopher D. ;

Annala, Matti ;

Aprikian, Armen ;

Armenia, Joshua ;

Arora, Arshi ;

Auman, J. Todd ;

Balasundaram, Miruna ;

Balu, Saianand ;

Barbieri, Christopher E. ;

Bauer, Thomas ;

Benz, Christopher C. ;

Bergeron, Alain ;

Beroukhim, Rameen ;

Berrios, Mario ;

Bivol, Adrian ;

Bodenheimer, Tom ;

Boice, Lori ;

Bootwalla, Moiz S. ;

dos Reis, Rodolfo Borges ;

Boutros, Paul C. ;

Bowen, Jay ;

Bowlby, Reanne ;

Boyd, Jeffrey ;

Bradley, Robert K. ;

Breggia, Anne ;

Brimo, Fadi ;

Bristow, Christopher A. ;

Brooks, Denise ;

Broom, Bradley M. ;

Bryce, Alan H. ;

Bubley, Glenn ;

Burks, Eric ;

Butterfield, Yaron S. N. ;

Button, Michael ;

Canes, David ;

Carlotti, Carlos G. ;

Carlsen, Rebecca ;

Carmel, Michel ;

Carroll, Peter R. ;

Carter, Scott L. ;

Cartun, Richard ;

Carver, Brett S. ;

Chan, June M. ;

Chang, Matthew T. ;

Chen, Yu .

CELL, 2015, 163 (04) :1011-1025

[2] The PARP superfamily [J].

Amé, JC ;

Spenlehauer, C ;

de Murcia, G .

BIOESSAYS, 2004, 26 (08) :882-893

[3] Relevance of DNA damage repair in the management of prostate cancer [J].

Banks, Patricia ;

Xu, Wen ;

Murphy, Declan ;

James, Paul ;

Sandhu, Shahneen .

CURRENT PROBLEMS IN CANCER, 2017, 41 (04) :287-301

[4] Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets [J].

Beltran, Himisha ;

Rickman, David S. ;

Park, Kyung ;

Chae, Sung Suk ;

Sboner, Andrea ;

MacDonald, Theresa Y. ;

Wang, Yuwei ;

Sheikh, Karen L. ;

Terry, Stephane ;

Tagawa, Scott T. ;

Dhir, Rajiv ;

Nelson, Joel B. ;

de la Taille, Alexandre ;

Allory, Yves ;

Gerstein, Mark B. ;

Perner, Sven ;

Pienta, Kenneth J. ;

Chinnaiyan, Arul M. ;

Wang, Yuzhuo ;

Collins, Colin C. ;

Gleave, Martin E. ;

Demichelis, Francesca ;

Nanus, David M. ;

Rubin, Mark A. .

CANCER DISCOVERY, 2011, 1 (06) :487-495

[5]

Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310

[6] Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination [J].

Buisson, Remi ;

Dion-Cote, Anne-Marie ;

Coulombe, Yan ;

Launay, Helene ;

Cai, Hong ;

Stasiak, Alicja Z. ;

Stasiak, Andrzej ;

Xia, Bing ;

Masson, Jean-Yves .

NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2010, 17 (10) :1247-+

[7] The Deubiquitinating Enzyme USP7 Regulates Androgen Receptor Activity by Modulating Its Binding to Chromatin [J].

Chen, Shu-Ting ;

Okada, Maiko ;

Nakato, Ryuichiro ;

Izumi, Kosuke ;

Bando, Masashige ;

Shirahige, Katsuhiko .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (35) :21713-21723

[8] A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study [J].

Coleman, Robert L. ;

Sill, Michael W. ;

Bell-McGuinn, Katherine ;

Aghajanian, Carol ;

Gray, Heidi J. ;

Tewari, Krishnansu S. ;

Rubin, Steven C. ;

Rutherford, Thomas J. ;

Chan, John K. ;

Chen, Alice ;

Swisher, Elizabeth M. .

GYNECOLOGIC ONCOLOGY, 2015, 137 (03) :386-391

[9] Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis [J].

Corcoran, Niall M. ;

Clarkson, Michael J. ;

Stuchbery, Ryan ;

Hovens, Christopher M. .

CLINICAL CANCER RESEARCH, 2016, 22 (13) :3132-3137

[10] Resistance to therapy caused by intragenic deletion in BRCA2 [J].

Edwards, Stacey L. ;

Brough, Rachel ;

Lord, Christopher J. ;

Natrajan, Rachael ;

Vatcheva, Radost ;

Levine, Douglas A. ;

Boyd, Jeff ;

Reis-Filho, Jorge S. ;

Ashworth, Alan .

NATURE, 2008, 451 (7182) :1111-U8

← 1 2 3 4 5 6 →